£490.00

The 2023-2028 Outlook for Heart Failure Drugs for US Zip Codes

Subjects

Price data last checked 18 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£490 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 73 days · 73 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 73 days • 1 price levels

Days at Price

Price Analysis

Most common price: £490 (73 days, 100.0%)

Price range: £490 - £490

Price levels: 1 different prices over 73 days

Description

This study covers the latent demand outlook for heart failure drugs across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for heart failure drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of heart failure drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CRC Health, Exelixis, GlaxoSmithKline, Johnson & Johnson, Lunan Pharmaceuticals Company, Merck & Company, Mylan NV, Novartis, Pfizer, Sanofi, Shanghai Haini Pharmaceutical Company, Ltd., The National Council for Palliative Care, and Valeant Pharmaceuticals International. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BSJJVSF9
Category: Books > Subjects
Domain: Amazon UK
Release Date: 09 January 2023
Listed Since: 27 January 2023

The 2023-2028 Outlook for Heart Failure Drugs for US Zip Codes

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Heart Failure Drugs in China

The 2023-2028 Outlook for Heart Failure Drugs in Japan

The 2023-2028 Outlook for Heart Failure Drugs in India

The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs for US Zip Codes

The 2013-2018 Outlook for Atrial Fibrillation (AF) Diagnostics and Therapeutics in India

Heart Failure I and II: The Comprehensive Guide to Pathophysiology and Clinical Care

The 2025-2030 World Outlook for Heart Health Ingredients

The 2023-2028 Outlook for Anti-Hypertensive Diuretic Drugs for US Zip Codes

Topics in Heart Failure Management

The 2025-2030 World Outlook for Cardiac Safety Services

Heart Failure I: A Comprehensive Guide to Pathophysiology and Clinical Care

Heart Failure II: A Comprehensive Guide to Pathophysiology and Clinical Care

The 2025-2030 World Outlook for Structural Heart Devices

Heart Failure Question Bank Part 3 Verified and Latest Updated Insights by 3 top AI models: 65 AI Consensus-Verified Multiple Choice Questions-Cases ... Smart as AIs! (www.EndlessMedical.Academy))

Patient Selection and Timing for Referral for Advanced Heart Disease Therapies, An issue of Heart Failure Clinics (Volume 22-2) (The Clinics: Internal Medicine, Volume 22-2)

The 2025-2030 World Outlook for Heart Healthy Ingredients

Advances & Innovations in Heart Failure (AIHF): A Textbook of Cardiology

The 2016-2021 Outlook for Atrial Fibrillation (AF) Diagnostics and Therapeutics in Japan

The 2023-2028 Outlook for Home Healthcare Devices for US Zip Codes

The 2023-2028 Outlook for Pharmaceutical Drug Deliveries for US Zip Codes

The 2023-2028 Outlook for Physical Fitness Cardiovascular Training Equipment for US Zip Codes

The 2023-2028 Outlook for Long Term Care for US Zip Codes

Heart Failure: A Companion to Braunwald's Heart Disease

The 2023-2028 Outlook for External Defibrillators for US Zip Codes